Apoptotic machinery diversity in multiple myeloma molecular subtypes

Frontiers in Immunology

Volumn 4, Issue DEC, 2013, Pages

  Gomez Bougie, Patricia ^a,b,c,d   Amiot, Martine ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CNRS   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Bcl 2 family; CCND1; MAF; MGUS; MMSET; Multiple myeloma

Indexed keywords

PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1;

APOPTOSIS; ARTICLE; CHROMOSOME 11; COMPARATIVE STUDY; EPIGENETICS; GENE DELETION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; MULTIPLE MYELOMA; PATHOPHYSIOLOGY; PHENOTYPE; TRISOMY;

EID: 84892378536     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00467     Document Type: Article

References (28)

1. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 106(1):296-303. doi:10.1182/blood-2005-01-0034
2. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 23(12):2210-21. doi:10.1038/leu.2009.174
3. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood (2006) 108(6):2020-8. doi:10.1182/blood-2005-11-013458
4. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J (2011) 30(18):3667-83. doi:10.1038/emboj.2011.307
5. Happo L, Strasser A, Cory S. BH3-only proteins in apoptosis at a glance. J Cell Sci (2012) 125(Pt:5):1081-7. doi:10.1242/jcs.090514
6. Willis SN, Fletcher JI, Kaufmann T, Van Delft MF, Chen L, Czobotar PE, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science (2007) 315(5813):856-9. doi:10.1126/science.1133289
7. Schmidt-Hieber M, Gutiérrez ML, Pérez-Andrés M, Paiva B, Rasillo A, Tabernero MD, et al. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells. Haematologica (2013) 98(2):279-87. doi:10.3324/haematol.2011.060632
8. Bodet L, Bougie-Gomez P, Touzeau C, Dousset C, Descamps G, Maiga S, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood (2011) 118(14):3901-10. doi:10.1182/blood-2010-11-317438
9. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood (2002) 100(1):194-9. doi:10.1182/blood.V100.1.194
10. Schwarze MM, Hawley RG. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res (1995) 55(11):2262-5.
11. Jourdan M, Veyrune J-L, De Vos J, Redal N, Couderc G, Klein B. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene (2003) 22(19):2950-9. doi:10.1038/sj.onc.1206423
12. Le Gouill S, Podar K, Harousseau JL, Anderson KC. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle (2004) 3(10):1259-62. doi:10.4161/cc.3.10.1196
13. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med (2013) 19(2):202-8. doi:10.1038/nm.3048
14. Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia (2013). doi:10.1038/leu.2013.216
15. Gomez-Bougie P, Bataille R, Amiot M. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol (2004) 34(11):3156-64. doi:10.1002/eji.200424981
16. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 334(6059):1129-33. doi:10.1126/science.1206727
17. Fernandez-Luna JL. Regulation of pro-apoptotic BH3-only proteins and its contribution to cancer progression and chemoresistance. Cell Signal (2008) 20(11):1921-6. doi:10.1016/j.cellsig.2008.04.015
18. Coultas L, Bouillet P, Stanley EG, Brodnicki TC, Adams JM, Strasser A. Proapoptotic BH3-only Bcl-2 family member Bik/Blk/Nbk is expressed in hemopoietic and endothelial cells but is redundant for their programmed death. Mol Cell Biol (2004) 24(4):1570-81. doi:10.1128/MCB.24.4.1570-1581.2004
19. Villunger A, Michalak EM, Coultas L, Müllauer F, Böck G, Ausserlechner MJ, et al. p53-and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science (2003) 302(5647):1036-8. doi:10.1126/science.1090072
20. Bodet L, Ménoret E, Descamps G, Pellat-Deceunynck C, Bataille R, Le Gouill S, et al. BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma. Br J Cancer (2010) 103(12):1808-14. doi:10.1038/sj.bjc.6605981
21. Ritchie A, Gutierrez O, Fernandez-Luna JL. PAR bZIP-bik is a novel transcriptional pathway that mediates oxidative stress-induced apoptosis in fibroblasts. Cell Death Differ (2009) 16(6):838-46. doi:10.1038/cdd.2009.13
22. Sturm I, Stephan C, Gillissen B, Siebert R, Janz M, Radetzki S, et al. Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ (2006) 13(4):619-27. doi:10.1038/sj.cdd.4401782
23. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood (2012) 119(9):2100-5. doi:10.1182/blood-2011-11-390658
24. Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood (2003) 101(4):1570-1. doi:10.1182/blood-2002-08-2436
25. Garand R, Avet-Loiseau H, Accard F, Moreau P, Harousseau JL, Bataille R. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia (2003) 17(10):2032-5. doi:10.1038/sj.leu.2403091
26. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, et al. Plasmablastic morphology-an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood (1998) 91(7):2501-7.
27. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol (2012) 87(1):78-88. doi:10.1002/ajh.22237
28. Billard C. BH3 mimetics: status of the field and new developments. Mol Cancer Ther (2013) 12(9):1691-700. doi:10.1158/1535-7163.MCT-13-0058